Browsing Radiotherapy and Imaging by author "Harrington, Kevin"
Now showing items 1-20 of 158
-
A convolutional neural network for contouring metastatic lymph nodes on diffusion-weighted magnetic resonance images for assessment of radiotherapy response.
Gurney-Champion, OJ; Kieselmann, JP; Wong, KH; Ng-Cheng-Hin, B; Harrington, K; et al. (ELSEVIER, 2020-07-01)BACKGROUND AND PURPOSE: Retrieving quantitative parameters from magnetic resonance imaging (MRI), e.g. for early assessment of radiotherapy treatment response, necessitates contouring regions of interest, which is ... -
A practical guide to the handling and administration of talimogene laherparepvec in Europe.
Harrington, KJ; Michielin, O; Malvehy, J; Pezzani Grüter, I; Grove, L; et al. (DOVE MEDICAL PRESS LTD, 2017-01-01)Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for the treatment of adults with unresectable ... -
A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer.
Wong, KH; Kuciejewska, A; Sharabiani, MTA; Ng-Cheng-Hin, B; Hoy, S; et al. (ELSEVIER IRELAND LTD, 2017-02-01)PURPOSE: This phase III, non-blinded, parallel-group, randomised controlled study evaluated the efficacy of Caphosol mouthwash in the management of radiation-induced oral mucositis (OM) in patients with head and neck cancer ... -
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27) -
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
Burtness, B; Haddad, R; Dinis, J; Trigo, J; Yokota, T; et al. (AMER MEDICAL ASSOC, 2019-08-01)IMPORTANCE: Locoregionally advanced head and neck squamous cell cancer (HNSCC) is treated curatively; however, risk of recurrence remains high among some patients. The ERBB family blocker afatinib has shown efficacy in ... -
Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models.
Burley, TA; Da Pieve, C; Martins, CD; Ciobota, DM; Allott, L; et al. (SOC NUCLEAR MEDICINE INC, 2019-03-01)In head and neck squamous cell cancer, the human epidermal growth factor receptor 1 (EGFR) is the dominant signaling molecule among all members of the family. So far, cetuximab is the only approved anti-EGFR monoclonal ... -
An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.
Henderson, DR; Murray, JR; Gulliford, SL; Tree, AC; Harrington, KJ; et al. (ELSEVIER SCIENCE LONDON, 2018-09-01)AIMS: There are limited data on dosimetric correlates of toxicity in stereotactic body radiotherapy (SBRT) for prostate cancer. We aimed to identify potential relationships between dose and toxicity using conventional ... -
An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
Patel, R; Barker, HE; Kyula, J; McLaughlin, M; Dillon, MT; et al. (2017-03)Purpose Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, ... -
An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
Patel, R; Barker, HE; Kyula, J; McLaughlin, M; Dillon, MT; et al. (ELSEVIER IRELAND LTD, 2017-03-01)PURPOSE: Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, ... -
Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies.
Roulstone, V; Mansfield, D; Harris, RJ; Twigger, K; White, C; et al. (BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to ... -
APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable.
Vile, RG; Melcher, A; Pandha, H; Harrington, KJ; Pulido, JS (AMER ASSOC CANCER RESEARCH, 2021-06-15)The apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC) family protects against infection by degrading incoming viral genomes through cytosine deamination. Here, we review how the potential to unleash these ... -
APOBEC3 Mediates Resistance to Oncolytic Viral Therapy.
Huff, AL; Wongthida, P; Kottke, T; Thompson, JM; Driscoll, CB; et al. (CELL PRESS, 2018-12-21)Tumor cells frequently evade applied therapies through the accumulation of genomic mutations and rapid evolution. In the case of oncolytic virotherapy, understanding the mechanisms by which cancer cells develop resistance ... -
APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy.
Driscoll, CB; Schuelke, MR; Kottke, T; Thompson, JM; Wongthida, P; et al. (NATURE PUBLISHING GROUP, 2020-02-07)APOBEC3B, an anti-viral cytidine deaminase which induces DNA mutations, has been implicated as a mediator of cancer evolution and therapeutic resistance. Mutational plasticity also drives generation of neoepitopes, which ... -
ART DECO (CRUK/10/018): dose escalated vs standard dose IMRT in locally advanced head and neck cancer
Nutting, C; Morden, J; Bernstein, D; Beasley, M; Cosgrove, V; et al. (ELSEVIER IRELAND LTD, 2017-03-01) -
Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk.
Dean, JA; Welsh, LC; McQuaid, D; Wong, KH; Aleksic, A; et al. (ELSEVIER IRELAND LTD, 2016-04-01)BACKGROUND AND PURPOSE: Current oral mucositis normal tissue complication probability models, based on the dose distribution to the oral cavity volume, have suboptimal predictive power. Improving the delineation of the ... -
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment.
Dillon, MT; Bergerhoff, KF; Pedersen, M; Whittock, H; Crespo-Rodriguez, E; et al. (AMER ASSOC CANCER RESEARCH, 2019-06-01)PURPOSE: ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to sensitize to chemotherapy and radiotherapy preclinically. Limited data have been published about the effect of these drugs on the ... -
Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck.
Welsh, L; Panek, R; Riddell, A; Wong, K; Leach, MO; et al. (NATURE PUBLISHING GROUP, 2017-01-03)BACKGROUND: Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radical chemo-radiation (CRT) frequently receive transfusion with packed red cells (PRCT) during radiotherapy on the basis that PRCT increases ... -
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
Bozhanova, G; Hassan, J; Appleton, L; Jennings, V; Foo, S; et al. (BMJ PUBLISHING GROUP, 2022-03-01)BACKGROUND: Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology ... -
Changes in multimodality functional imaging parameters early during chemoradiation predict treatment response in patients with locally advanced head and neck cancer.
Wong, KH; Panek, R; Dunlop, A; Mcquaid, D; Riddell, A; et al. (SPRINGER, 2018-05-01)OBJECTIVE: To assess the optimal timing and predictive value of early intra-treatment changes in multimodality functional and molecular imaging (FMI) parameters as biomarkers for clinical remission in patients receiving ... -
Changing paradigms in the treatment of residual/recurrent head and neck cancer: implications for dysphagia management.
Brady, GC; Hardman, JC; Paleri, V; Harrington, KJ; Roe, JWG (LIPPINCOTT WILLIAMS & WILKINS, 2020-06-01)PURPOSE OF REVIEW: Despite advances in head and neck cancer treatment provision, recurrence rates remain high with the added risk of successfully treated patients developing a second primary. We report on the management ...